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Case Presentation
On 2nd July 2013, a 29-year-old HIV-positive woman presented herself to the outpatient clinic
at the Infectious Diseases Institute in Kampala, Uganda. Her weight had decreased from 46 kg
to 42 kg in the past few weeks. In addition, she complained about abdominal pain, diarrhea,
vomiting, and evening fevers during the week leading up to her visit (see Table 1 and Fig 1 for
patient characteristics). Her CD4 T cell count in June 2013 was 34 cells/μl, and she had docu-
mented second-line antiretroviral treatment (tenofovir disoproxil fumarate, emtricitabine, and
lopinavir-ritonavir) failure. She admitted to taking her medications irregularly and was on tri-
methoprim-sulfamethoxazole prophylaxis. Her last HIV-1 RNA viral load in June 2013 was
199,994 copies/ml. Based on her immunosuppression and symptoms, we screened her for
tuberculosis (TB). At the time of screening, she could not produce sputum, but an abdominal
ultrasound in late June 2013 showed a lymphadenopathy. A chest X-ray was not carried out at
baseline, as it would not have changed the clinical decision to treat the presumptive diagnosis
of extrapulmonary TB. Her glomerular filtration rate (GFR) was 55 mL/min, the liver enzyme
alanine aminotransferase was 33 IU/L (normal range 0–35 IU/L), and her albumin level was
slightly decreased (35.5 g/L; normal range 38–47 g/L).
Progress
She was started on antituberculosis treatment consisting of rifabutin, isoniazid, ethambutol,
and pyrazinamide on 1st August 2013. During follow-up, the patient claimed to adhere to her
treatments and reported that the abdominal pain, vomiting, diarrhea, and evening fever
stopped; nevertheless, she continued to lose weight in the weeks that followed. At the follow-up
visit on 26th September 2013, the patient reported the development of hyperpigmented, pro-
gressive nodular, dome-shaped, non-itchy, and well-demarked facial skin lesions that had
increased in number and size during the previous four weeks (see Fig 2A). She did not have
prior lesions and complained again about abdominal pain, diarrhea, vomiting, and evening
fevers. Despite adherence to treatment, she had lost about 15% of her body weight since treat-
ment began. Apart from generalized weakness and a hepatomegaly (approximately 5 centime-
ters under the right costal margin), no abnormalities were found during physical examination,
especially neither palpable lymph nodes nor oral or eye symptoms.
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What Is Your Differential Diagnosis?
Despite the possible explanation of (multi-) drug resistant TB, the continued weight loss and
the appearance of new lesions warranted a revision of the initial diagnosis and additional inves-
tigations. In this woman, the differential diagnoses included but were not limited to TB of the
skin, Kaposi sarcoma, atypical mycobacteria infection, disseminated fungal diseases, and neo-
plastic mimics of Kaposi sarcoma–like cutaneous T cell lymphoma. The situation was compli-
cated by the fact that the patient had a high HIV-1 viral load at the beginning of TB treatment,
and restarting her antiviral treatment together with her TB treatment could have led to clinical
deterioration because of immune reconstitution inflammatory syndrome occurrence.
What InvestigationsWould You Ask For?
In our resource-limited setting, we opted for a stepwise approach. A chest X-ray was unre-
markable (not shown); the serum antigen test for Cryptococcus neoformans was negative. A
skin biopsy showed Histoplasmosis capsulatum infection. We did not have access toH. capsula-
tum detection tests. For a review of molecular epidemiology, clinical findings, diagnosis, and
treatment of histoplasmosis in HIV-infected patients, please refer to the review of Adenis [1].
Table 1. Patient characteristics.
Date Weight
(kg)
Medication Symptoms Laboratory findings Remarks
04-Jun-
2013
46 ART, TMP-SMX Routine follow-up
02-Jul-
2013
42 ART, TMP-SMX Vomiting, abdominal pain,
diarrhea, evening fevers
CD4: 34 c/μLVL: 199,994
c/ml
30-Jul-
2013
42 ART, TMP-SMX Vomiting, abdominal pain,
diarrhea, evening fevers
TB screening, US; abdomen showed
lymphadenopathy
01-Aug-
2013
n.d. ART, TMP-SMX, Rif/
HZE
Vomiting, abdominal pain,
diarrhea, evening fevers
ALT: 33 IU/LAlbumin: 35.5
g/LGFR: 55 ml/min
Start TB treatment
12-Aug-
2013
41 ART, TMP-SMX, Rif/
HZE
Clinical improvement
26-Sep-
2013
36 ART, TMP-SMX, Rif/
HZE
Vomiting, abdominal pain,
diarrhea, development of skin
lesions
Serum CrAg negative Hepatomegaly, CXR normal, skin
biopsy shows histoplasmosis
08-Oct-
2013
n.d. ART, TMP-SMX, EH,
Ampho
Clinical worsening ALT: 25 IU/LGFR: 57 ml/
min
Switch to EH, start histoplasmosis
treatment
28-Oct-
2013
n.d. ART, TMP-SMX, EH,
Fluconazole
Generalized body weakness GFR: 46 ml/min US; abdomen normal
22-Feb-
2014
46 ART, TMP-SMX, EH,
Fluconazole
Skin lesions healed GFR: 50 ml/min Routine follow-up
03-Mar-
2014
48 ART, TMP-SMX,
Fluconazole
Completion TB treatment
04-Dec-
2014
n.d. ART, TMP-SMX Fluconazole stopped
16-Jun-
2015
49 ART, TMP-SMX CD4: 19 c/μLVL: 252,000
c/ml
Routine follow-up
kg, kilogram; ART, antiretroviral treatment; TMP-SMX, trimethoprim-sulphamethoxazole; CD4, CD-4 T cell count; c/μL, cells per microliter; VL, HIV-1 RNA
plasma viral load; c/ml, copies per milliliter; TB, tuberculosis; US, ultrasound; n.d., not done; Rif/HZE, rifabutin, isoniazid, pyrazinamide, ethambutol; CXR,
chest X-ray; ALT, alanine aminotransferase; IU/L, International Unit per liter; g/L, gram per liter; GFR, glomerular filtration rate; ml/min, milliliter per minute;
CrAG, cryptococcal antigen; EH, ethambutol, isoniazid; Ampho, amphotericin B deoxcholeate.
doi:10.1371/journal.pntd.0004430.t001
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Fig 1. Schematic representation of the patient’s 18-month follow-up with the clinical symptoms, most important diagnostic findings, and
treatment timeline. Please note that the scheme is not to scale.
doi:10.1371/journal.pntd.0004430.g001
Fig 2. The patient’s skin lesions before and during antifungal treatment. A) Patient presented with skin lesions on 26th September 2013. A biopsy was
taken from the large lesion and led to a diagnosis of Histoplasma capsulatum (see arrow). B) Clinical response after a 14-day course of amphotericin B
deoxycholate (0.7 mg/kg body weight), followed by six days of fluconazole (400 mg twice daily) maintenance therapy. C) Four months into maintenance
treatment, the lesions had resolved.
doi:10.1371/journal.pntd.0004430.g002
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HowWould You Manage This Case?Would You Continue TB
Treatment?
The woman was hospitalized for treatment of disseminated histoplasmosis. Treatment for
severe disseminated histoplasmosis ideally consists of liposomal amphotericin B 3 mg/kg/d for
seven to 14 days or until clinical improvement, followed by itraconazole 200 mg three times
daily for three days, then 200 mg twice daily for at least 12 months where available [2]. In our
setting, only amphotericin B deoxycholate and fluconazole were available. We treated the
patient with 0.7 mg/kg amphotericin B deoxycholate for 14 days, then switched to fluconazole
400 mg twice daily for two weeks and afterwards to 400 mg once daily for a maintenance
phase.
Because of the initial clinical response to TB treatment, the TB treatment was continued.
Based on the Ugandan national guidelines, and to avoid rifampicin-lopinavir/ritonavir interac-
tion, we choose ethambutol/isoniazid for maintenance treatment, although this regime has
been shown to be inferior to rifampicin/isoniazid [3].
Follow-up
The lesions responded very well to amphotericin B deoxycholate treatment, and the patient’s
weight began to increase (see Table 1 and Fig 1). A follow-up abdominal ultrasound on 28th
October 2013 showed that the lymphadenopathy had been resolved. During the amphotericin
B deoxycholate therapy, we regularly monitored serum electrolytes and the GFR. The GFR
remained stable over time. Four months into antifungal treatment, the patient reached her
baseline body weight of 46 kg and the lesions had healed (see Fig 2B and 2C).
The patient was seen regularly, and the fluconazole was stopped on 4th December 2014. She
did not develop any new skin lesions and was last seen on 16th June 2015. On that day, her
CD4 T cell count was 19 cells/microliter, and her HIV-1 RNA viral load was 252,000 copies/
milliliter. Her body weight was stable at 49 kg, and the patient did not have any clinical com-
plaints. The patient is still on failing second-line antiretroviral treatment and has been enrolled
in the control arm of the AIDS Clinical Trial Group Study A5288 (Management Using the Lat-
est Technologies in Resource-Limited Settings to Optimize Combination Therapy After Viral
Failure).
Case Discussion
This case illustrates the challenges of diagnosing (disseminated) histoplasmosis in our particu-
lar setting. Without skin involvement, the diagnosis would have been difficult to ascertain, as
H. capsulatum serum antigen tests were not available. The overlap of histoplasmosis and TB
clinical findings is shown in Table 2.
Data on drug-resistant, extrapulmonary TB in Uganda is only anecdotal, but the first
national survey published in 2013 showed that the 1.4% of previously untreated sputum
Table 2. Common clinical symptoms of disseminated histoplasmosis and tuberculosis.
Fever
Weight loss
Lung disease
Hepatosplenomegaly
CNS complaint and/or meningitis
Lymphadenopathy
doi:10.1371/journal.pntd.0004430.t002
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smear–positive TB patients were multidrug-resistant [4]. Because the patient was critically ill
and response to TB treatment can take several weeks or even months, we decided to continue
TB treatment. In view of the response to the antifungal treatment, continuation of TB treat-
ment should be seen as critical in retrospect.
Because of financial constraints, state-of-the-art maintenance treatment with itraconazole
could not be provided. In addition, use of itraconazole warrants pharmacological monitoring,
which was not available in our setting. Nevertheless, the patient responded well to fluconazole.
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Key Learning Points
• Diagnosis of TB can be challenging in resource-limited settings. No “antibiotic trial”
for TB diagnosis should be given.
• The clinical symptoms of histoplasmosis and TB overlap, which results in underdiag-
nosis of histoplasmosis in Africa, butH. capsulatum polysaccharide can be detected
with high sensitivity and specificity in serum and bronchioloalveolar lavages.
• Fluconazole has been shown to be less effective in the maintenance phase than itraco-
nazole in clinical trials but has been used on an ad-hoc basis. A maintenance phase
should be carried out for at least 12 months, and lifelong suppressive therapy may be
required if immunosuppression cannot be reversed.
• Although consolidation phase treatment with rifampicin/isoniazid has been proven to
be superior to ethambutol/isoniazid, this treatment circumvented the hepatotoxic
interaction between the protease inhibitor and rifampicin, and eight months of etham-
butol/isoniazid continues to be the standard in Uganda.
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